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Riassunto 
 
I virus oncolitici sono un tipo virus che in maniera specifica 
replicano, infettano e distruggono solo le cellule tumorali. Numerosi 
studi clinici hanno dimostrato che il solo approccio oncolitico non può 
distruggere in modo efficace una grossa massa tumorale, limitando, 
quindi, l’efficacia di una viroterapia. La combinazione di adenovirus 
oncolitici con farmaci chemioterapici ha fornito promettenti risultati 
grazie all’azione sinergica del virus con un farmaco ed è considerato 
come un potenziale approccio per la terapia contro il cancro. In questo 
studio, abbiamo messo a punto un modello che utilizza adenovirus 
oncolitico come “scaffold” per veicolare farmaci attivi. Abbiamo, 
prima di tutto, sviluppato una strategia per coniugare peptidi sul 
capside virale, che si basa su interazioni elettrostatiche. Sulla base di 
risultati da noi ottenuti precedentemente, abbiamo utilizzato il 
dipeptide L-carnosina (β-Ala-His). L-carnosina è un dipeptide naturale 
con molteplici funzioni biologiche, tra le quali anche una significativa 
attività antiproliferativa sia in vitro che in vivo. La molecola di L-
carnosina, caricata positivamente per l’aggiunta di una coda di sei 
lisine (Carnosina6K), è stata combinata con la superficie di un virus 
oncolitico, caricato negativamente, consentendo così la formazione di 
un complesso (Ad5D24CpG-Carnosine6K). Utilizzando differenti 
linee cellulari, abbiamo osservato che 100vp del complesso, rispetto 
ad un adenovirus non coniugato, riducono in maniera significativa la 
proliferazione cellulare e la produzione di ATP. Nelle stesse linee 
cellulari il complesso aumenta l’efficienza di trasduzione ed il titolo 
infettivo del vettore virale rispetto ad un adenovirus oncolitico non 
coniugato. Infine, l’attività oncolitica del complesso è stata analizzata 
in un modello xenografico di tumore del polmone e del colon. Topi 
nudi, nei quali cellule neoplastiche A549 e HCT-116 sono state 
impiantate sottocute nei fianchi, sono stati trattati a livello intra-
tumorale a 0, 2 e 5 giorni con 1x108 particelle virali. La crescita 
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tumorale è stata seguita nel tempo ed i risultati ottenuti dimostrano 
una riduzione del tumore nei topi trattati con il complesso rispetto a 
quelli trattati con il solo virus o con Carnosina6K. Successivamente 
abbiamo investigato i possibili meccanismi molecolari responsabili 
degli effetti del complesso sulla riduzione della crescita tumorale. I 
risultati ottenuti suggeriscono che il complesso (del virus oncolitico 
con la L-carnosina modificata) induce apoptosi e determina un 
aumento dell’autofagia (LC3), migliorando l’efficacia del processo di 
oncolisi mediato dall’adenovirus. In conclusione, il presente modello, 
una volta validato, potrebbe rappresentare una nuova strategia per il 
rilascio di un farmaco nella terapia contro il cancro. 
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Abstract 
 
Oncolytic viruses are viruses that are able to replicate 
specifically and infect and destroy only tumor cells. Many clinical 
studies have shown that the oncolytic approach alone could not 
efficiently destroy the large tumor mass, thus by limiting an efficacy 
virotherapy. Combination of oncolytic adenoviruses (Ads) and 
chemotherapeutic drugs has shown promising therapeutic results due 
to the synergistic action of virus and drug and is considered as a 
potential approach for cancer therapy. In the present study, we have 
optimized a model to use oncolytic adenovirus as a scaffold to deliver 
active drugs. First, we have developed a strategy to conjugate peptides 
on viral capsid, based on electrostatic interactions. We have utilized 
the L-carnosine (β-Ala-His) dipeptide, according to our previous 
results. L-carnosine is a naturally occurring histidine dipeptide, with a 
number of biological functions, including a significant 
antiproliferative activity both in vitro and in vivo. L-carnosine 
positively charged, consisting of a tail of six lysines (Carnosine6K), 
has been combined with the surface of oncolytic adenovirus that is 
negatively charged, to allow the formation of a complex 
(Ad5D24CpG-Carnosine6K).  
We have observed using different cancer cell lines that complex at 
100vp, is able to reduce significantly cell proliferation and ATP 
production compared to an uncoated oncolytic adenovirus. Finally, the 
oncolytic activity of the complex was tested in a lung and colon 
cancer xenograft model. Nude mice bearing A549 and HCT-116 cell 
tumors in the flanks were treated intra-tumorally and each tumor was 
treated with 1x108 VP. The tumor growth was followed over time, our 
results show a reduction in tumor growth in mice treated with 
complex compared to the mice treated with virus alone or 
Carnosine6k.  Later, we have investigated the molecular mechanisms 
underlying the effects by oncolytic virus coated with modified L-
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carnosine on tumor growth reduction. Our results suggest that the 
oncolytic virus coated with modified L-carnosine induces apoptosis, 
increases autophagy (LC3), by improving the efficacy of Ad-mediated 
oncolysis. In conclusion, once validated the proposed model could be 
used as a novel drug delivery system for cancer therapy. 
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1 Introduction 
 
Cancer is a neoformation of cells that grow uncontrolled and is 
independent compared to the normal tissue of origin. A tumor can be 
caused by mutations in genes that control cell growth, alterations of 
genetic nature (which convert a proto-oncogene into an oncogene), or 
by infection by oncogenic viruses. The cell, as a result of these events, 
is not able to control the correct way of its growth and its 
differentiation. Moreover cancer is a metabolic disorder producing 
energy to survive when resources are limited and diverting metabolic 
intermediates in pathways that promote cell proliferation (Porporato et 
al., 2011). The tumor cells use the intermediates of the glycolytic 
process for the synthesis of anabolic compounds essential to cell 
survival. They use glucose 6-phosphate for the synthesis of glycogen 
and ribose 5-phosphate, dihydroxyacetone phosphate for the synthesis 
of triglycerides and phospholipids, and phosphoenolpyruvate to 
pyruvate and the formation of numerous amino acids. This anabolic 
activity is also favored by an increase in the expression of a particular 
isoform of pyruvate kinase (PKM2), responsible for the accumulation 
of intermediates of glycolysis. 
Cancer is a major cause of death globally. Despite the improvements 
made in recent years in conventional cancer treatments, the number of 
cancer cases is still on the rise (Eaton, 2003). Although treatments 
have improved significantly in the last decades, conventional 
chemotherapy or radiotherapy still have limited effects against many 
forms of cancer, not to mention a lot of treatment-related side effects. 
Novel more effective and less toxic therapeutic strategies are needed 
to improve the treatments. To address these issues, numerous attempts 
are underway. All these are driven by an improved understanding of 
the molecular basis of cancer in order to improve treatment strategies. 
It has been showed that monotherapy with oncolytic adenovirus can’t 
eradicate tumour mass. Therefore nowadays many effort has been put 
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to combine oncolytic adenoviruses with chemotherapy, radiation and 
immunotherapy. Cancer microenvironment is highly 
immunosuppressed, therefore its important to not only to focused on 
cancer direct lysis (oncolytic adenovirus leads to direct lysis of cancer 
cells), but above all immunostimulation of the host immune system 
(immunotherapy). Therefore new treatment modalities are highly 
needed. 
 
1.1 Virotherapy 
 
Virotherapy is the name of the approach that enables the use of 
viruses as therapeutic tools in the experimental medicine. This 
approach consists of genetically modifying viruses in a such a way 
that they lose some functions and acquire some other ones. It utilizes 
genetically engineered viruses for selective infection and killing of 
tumor cells while leaving normal cells relatively unarmed. They 
achieve this by a number of mechanisms, including direct lysis, 
apoptosis, expression of toxic proteins, autophagy and shutdown of 
protein synthesis, as well as the induction of anti-tumoral immunity.  
Indeed, virotherapy can be split into three main branches:  
- The development of oncolytic viruses, to selectively kill cancer cells 
and to be used thus as antitumor agents.  
- Gene therapy, that involves the use of different viruses and 
techniques to deliver genes or factors that change the gene expression 
of the host cells and tissues to cure genetic diseases and other 
disorders. It is a form of molecular medicine that promises to provide 
new treatment for a large number of inherited and acquired human 
diseases and is used where conventional clinical procedures are less 
effective. 
-Viral immunotherapy is a third branch where viral vectors deliver 
immune system-targeting factors to change the immune 
responsiveness of the hosts. Thus, new vaccines may be generated and 
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many diseases may be cured with the immunotherapy is an 
experimental approach to treat cancer. 
 
The origin of oncolytic virotherapy comes from rare anecdotal reports 
of cancer patients who experience a temporary remission after 
contracting a viral infection. These cases usually involve patients with 
hematologic malignancies, associated immunosuppression and a 
subsequent naturally acquired infection such as influenza, chicken pox 
or measles. The obvious hypothesis followed that optimized 
intentional viral inoculation could be a cure for cancer. Clinical trials 
of several naturally-occurring oncolytic viruses were started back in 
the 1950s. Early work in the area was greatly affected from a lack of 
standardization of study protocols (Moore, 1954). An example, 
clinical trials were conducted using serum from viremic blood donors 
(Hoster et al., 1949; Taylor, 1953). In spite of these challenges, some 
of these early clinical studies established transient responses with only 
a few mild side effects and suggested the potentiality of oncolytic 
virotherapy (Norman et al., 2001). The renaissance of this field in 
recent years came from advances in knowledge about the interactions 
between virus and host at the molecular level, combined with the 
possibility of genetic engineering of the viruses. 
 
Viral oncolysis (also termed virotherapy) has been studied intensively 
over the past two decades to develop a new strategy for cancer therapy 
(Pennisi, 1998).  
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Figure 1 Schematic diagram of oncolytic virotherapy (Cross and Burmester, 
2006). The intratumoral injection of an oncolytic adenovirus leads to the eradication 
of the tumor. 
 
Many different viruses have been investigated for their potential use 
as virotherapy agents, including influenza, Herpes Simplex Virus 1 
(HSV-1), Vesicular Stomatitis Virus (VSV), Adenovirus, Vaccinia 
Virus, Coxsackie Virus, Measles Virus and Poliovirus. The potential 
of oncolytic virus, once limited by the limited knowledge of virus 
properties, is now surpassed by the progress in the fields of virology, 
immunology and cancer is no longer limited by the properties of the 
viruses in nature. The new oncolytic viruses are engineered to 
overcome limits related to efficacy and safety of these therapeutic 
agents. 
 
1.2 Adenovirus structure, life cycle and genome 
 
Adenoviruses (Ads) were isolated in 1953 from human adenoid 
tissue samples in culture undergoing spontaneous regression (Rowe et 
al., 1953). Since then Ads have become the most widely used for gene 
delivery and therapy also due to the efficient production. 
 
They are common opportunistic pathogens rarely associated with 
severe clinical symptoms in healthy adults (Lenaerts et al., 2008). It is 
well known that Ads are able to infect humans via the respiratory, the 
fecal-oral, or the ocular conjunctival routes. Illnesses are generally 
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mild in immunocompetent humans, but can spread and cause disease 
in patients with compromised immunity, such as AIDS patients and 
transplant recipients (Kojaoghlanian et al., 2003). Adenoviruses 
belong to the family of Adenoviridae, which is subdivided into four 
genera (Siadenovirus, Aviadenovirus, Atadenovirus, and 
Mastadenovirus) (Davison, A. J et al; 2003). All human adenoviruses 
belong to the genera of Mastadenovirus. Adenoviruses are 
icosahedral, non-enveloped viruses with a dsDNA genome varying 
between 25-45 kilobases in size with inverted terminal repeats (ITRs) 
at both termini and a terminal protein attached to the 5´ends (Russell, 
2000). The icosahedral capsid is formed by three major proteins, of 
which the hexon trimers are most abundant (Figure 2) (Nemerow et 
al., 2009). Each of the twelve vertices of the capsid also contains a 
pentameric protein, a penton base that is covalently attached to the 
fiber. The fiber is a trimeric protein that protrudes from the penton 
base and is a knobbed rod-like structure. Each has an N-terminal tail, a 
shaft with repeating sequences, and a C-terminal knob domain with a 
globular structure. The knob domain is mainly responsible for binding 
the target cellular receptor and its globular structure presents a large 
surface for lateral and apical binding. The fiber proteins of 
adenoviruses from different subgroups most distinctively differ in 
length and ability to bend. As in many other nonenveloped viruses, Ad 
virions are mainly constituted of proteins and DNA, and also some 
carbohydrates can be found (Russell, 2000). 
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Figure 2 Structure of Adenovirus. Adenoviruses are non-enveloped particles of 
70-90 nm in diameter with an inner nucleoprotein core. The double stranded DNA is 
packaged within an icosahedral protein capsid. The major protein of the capsid is the 
trimeric hexon that constitutes the 20 triangular faces of the icosahedron. Penton 
capsomeres, formed by the protein of the penton base and fiber, are localized at each 
of the 12 vertices of the Ad capsid and to which the 12 protruding fiber homotrimers 
attach(modified fromRussell 2009). 
 
 
Adenovirus life cycle can be characterized by five stages: binding, 
entry, escape, translocation, and nuclear transport. Initially the fiber 
knob binds a primary receptor with high affinity and once the virus is 
tethered on the cell surface, low affinity binding to secondary 
receptors leads to internalization (Wickham et al., 1993). The 
internalization via dynamin dependent chlatrin-mediated endocytosis. 
Escape from the endosome into the cytosol occurs within minutes and 
is dependent on the acidification of the endosome, this triggers 
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changes in the adenoviral capsid resulting in the lysis of the endosome 
membrane. Once in the cytosol, adenoviral capsids translocate 
towards the nucleus along the microtubules by interacting with 
cellular molecular motors, such as cytoplasmic dynein. Thereafter, the 
adenoviral genome is transported inside the nucleus via nuclear pores 
(Figure 3). 
 
 
Figure 3 Adenoviral replication cycle. Viruses first attach to the coxsackie 
adenovirus receptor (CAR) followed by an interaction with cellular integrins 
resulting in internalization of the virus via receptor- mediated endocytosis. In the 
endosomes, the viral genome is released from the viral capsid and there after 
transported into the nucleus for DNA replication. Structural viral proteins assemble 
together with viral genomes in the nucleus followed by cell lysis and release of 
newly synthesized virions (modified from Bryan E et al; 2013). 
 
The human Ad replication cycle has been mainly studied in Ad2 and 
Ad5 serotypes as models and so far it has been found equivalent to the 
other serotypes. The viral replication cycle is divided into two phases 
that are separated by the onset of viral replication. The early phase 
starts with the viral infection with the host cell and also includes 
adsorption, penetration, movement of partially uncoated virus to a 
Introduction 
 
19 
 
 
nuclear pore complex, transport of viral DNA through the nuclear 
pore complex into the nucleus and finally expression of an early set of 
genes. Early viral gene products mediate viral gene expression, DNA 
replication, cell cycle progression, and block of apoptosis and 
antagonize a variety of host antiviral measures. The late phase begins 
with expression of late viral genes and assembly of progeny virions. 
 
1.3 Adenoviral genome 
 
Adenoviral transcription can be described as early and late, 
characterized by the expression of different viral genes. Dividing the 
genome into immediate early (E1A), early (E1B, E2, E3, E4), 
intermediate (IX, Iva), and late (L1-L5) genes (Figure 4). The first 
transcription unit to be expressed is the E1A. The E1A proteins 
stimulate the transcription of other early genes and modulate the 
expression of cellular genes involved in the transition into S-phase, 
making the cell more susceptible to viral DNA replication (Berk, 
1986). The E1B proteins suppress cell death elicited in response to 
unregulated cell proliferation signals, including those mediated by 
E1A. The E2 gene products provide the replication machinery for 
viral gene products. E3 gene products are not essential for virus 
replication, in vitro it has been correlated with the control of various 
host immune responses. 
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Figure 4 Representation of adenovirus genome. Right part: Scheme of the 
adenovirus genome. E = early genes, L = late genes, MLP = major late promoter, Ψ 
= packaging signal, which is as a starting point for virus replication, LITR/RITR = 
left/right inverted terminal repeats, which are crucial for complementary DNA 
pairing during virus replication. Modified from: (Russell 2000).  
 
E4 gene products have been implicated in many events that occur as 
the late program starts. E4 regulates transcription, the transition from 
early to late gene expression, viral replication and assembly of virions. 
The late genes L1-L5 result in the production of the viral structural 
components and encapsidation and maturation of the particles in the 
nucleus (Russell et al; 2000). Ads, especially serotype 5, are the most 
studied thus used in gene therapy approaches, including oncolytic 
virotherapy. Ads are human pathogens, causing only mild respiratory 
and conjunctival infections. Their genome does not integrate into host 
DNA, resulting in low risk of mutagenesis. The limited duration of 
viral gene expression makes Ads suitable for gene therapy 
applications. Moreover these are optimal vectors where only transient 
gene expression is needed (e.g. cancer therapy) (Robbins and 
Ghivizzani, 1998; Russell, 2009). To make the adenovirus tumor-
specific, a modification in the viral E1A gene (deletion 24 bp) is 
made. This deletion makes the expressed, defective E1A protein 
RITR LITR 
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unable to bind to a retinoblastoma protein (pRb). The pRb is free to 
bind to the E2F-1 transcription factor, preventing the cell to pass to 
the S-phase of cell cycle. These delta24 viruses can only replicate in 
cells where the pRb-E2F-1 interaction is not necessary (i.e. tumor 
cells). In many cancers the pRb is mutated and E2F-1 is constantly 
present in the cells. In these cells E2F-1 is able to activate genes that 
facilitate the G1/S transition and S-phase so that the viral genome can 
be replicated. On the other hand a deletion of E1B allows p53 to 
induce apoptosis in infected cells, aborting the replication and spread 
of the virus. 
 
1.4 Mechanism of tumor selectivity for Ads 
 
One potential approach to treat cancer refractory is to use 
oncolytic viruses (Figure 5). Oncolytic virotherapy exploits the 
normal life cycle of a virus in order to kill tumor cells. Oncolytic 
adenoviruses are either genetically engineered leaving normal cells 
unharmed or naturally attenuated and non-pathogenic in humans 
(Post, 2002). Normal tissue is kept safe since viruses are targeted 
towards tumor cells leading to no replication in normal cells (Khuri et 
al., 2000). Ideally, oncolytic virus should also be able to spread 
through the circulation into distant metastases (Liu and Kirn, 2007). 
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Figure 5 Concept of oncolysis. Oncolytic viruses are derived from human viruses 
via genetic modifications. Such modifications include the mutation or deletion of 
viral genes, or the insertion of tumor-specific promoters. Oncolytic adenoviruses 
infect tumor cells, replicate their genome, assemble new viral particles and kill the 
host tumor cell by lysis, resulting in the release of the progeny viruses. This new 
virus generation spreads, and starts a new cycle of virus replication and tumor cell 
killing. Thus, an ideal oncolytic virus represents an efficient and specific anti-cancer 
agent. 
 
The most used in oncolytic cancer therapy are specific class of 
adenovirus, which can kill tumor cells by tumor cell-specific 
replication (Mathis et al., 2005; Ribacka et al., 2008). 
Adenoviruses have become the most widely used and most 
extensively studied viruses for gene delivery/therapy purposes, being 
easy to manipulate and very safe in vitro and in vivo. Numerous pre-
clinical studies were conducted using adenoviral vectors to transfer 
tumor suppressor genes or as oncolytic viruses (Alemany et al., 2000). 
Oncolytic adenoviruses are genetically manipulated human 
adenoviruses that acquired a replication phenotype in tumor cells, but 
show a more restricted phonotype in normal cells. Several features of 
wild type adenoviruses can be modified to acquire tumor replication 
properties (Chiocca, 2002). There are different ways in order to 
develop tumor specificity in oncolytic adenoviruses: 
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• by altering viral genes that attenuate replication in normal 
tissue but not in tumor cells;  
• by placing viral genes that initiate viral replication under the 
control of promoter sequences that are active only in tumor 
cells;  
• by the modification of viral coat proteins that function in host 
cell infection. 
 
Various types of oncolytic Ads have been developed, and can be 
mainly classified into 2 groups. One shows tumor-selectivity via 
deletion of E1B-55K gene, which are dispensable for the replication 
of Ads in tumor cells. The second type of oncolytic Ads possess the 
E1 gene expression cassette driven by tumor-specific promoters. For 
example, by altering a region of the E1B gene, the adenovirus can 
selectively replicate in p53-deficient (i.e.tumour) cells and leave p53-
competent cells intact. In addition E1B-55KDa mediates late-viral 
RNA transport and the loss of E1B-55KDa is restrict to the viral 
replication of tumor cells capable of taking over the RNA export 
function of the viral gene product (O’Shea et al., 2005). 
 
1.5 Oncolytic Adenoviruses and human cancer 
 
Cancer is one of the leading causes of death worldwide. The 
discovery of new technologies has led to the development of more 
sensitive diagnostic methods and new types of treatment. However, 
conventional therapies such as radiotherapy and chemotherapy, have 
shown limitations related to side effects and the impossibility to 
prevent relapses. 
Cancer cells have undergone a mini-evolution (point-mutations, larger 
chromosomal shifts and alterations), providing them with selective 
growth advantages over normal cells (Cahill et al., 1999). While 
cancer cells gain growth, they can simultaneously lose critical 
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components of the intracellular defense mechanisms and thus become 
fertile ground for the replication of many viruses. One strategy for the 
treatment of cancer is the use of oncolytic adenoviruses for cancer 
destruction since they have the potential to take advantage of cancer 
specific changes to replicate specifically in tumor cells (Pesonen et al., 
2011). 
Oncolytic adenoviruses are engineered to infect cancer cells and 
induce cell death through the propagation of the virus, expression of 
cytotoxic proteins and cell lysis (Mullen and Tanabe, 2003). Oncolytic 
viruses replicate preferentially in cancer cells and can destroy those 
cells at the end of replication cycles by lysis. The viral progeny are 
then released and they can infect neighboring cells, which results in 
multiple steps of infection, replication, lysis and spread throughout the 
tumor, all while sparing normal cells, hence toxicity is limited. The 
limitations in success may be due to the intrinsic biological properties 
of the tumor targets. 
In 2005, State Food and Drug Administration in China approved the 
first oncolytic adenovirus as a drug for head and neck squamous cell 
carcinoma (Yamamoto and Curiel, 2010). This to bring the hope that 
oncolytic adenoviruses can be used for the treatment of cancer. The 
efficacy of oncolytic adenoviruses in cancer gene therapy can be 
increased by arming the virus with a therapeutic transgene. In this 
regard oncolytic adenoviruses have been engineered to express tumor 
associated antigen, co-stimulatory molecules, such as CD40 ligand 
(CD40L) and CD80, immunostimulatory cytokines, including 
interleukin IL-2, IL-12, IL-15, IL-23, IL-24 and granulocyte 
macrophage colony-stimulating factor (GM-CSF) (Pol J et al; 2014). 
The first generation of oncolytic adenovirus, ONYX-015 (also known 
as dl1520, H101 in China), is a genetically modified adenovirus with 
deletion of the 55 kD gene in the E1B region (Nemunaitis et al., 
2001). This virus is the only approved for oncolytic therapy, it 
contains a deletion in the E1B gene, preventing the formation of a 
Introduction 
 
25 
 
 
functional E1B-55kDa protein. With this mutation, ONYX-015 was 
expected to replicate only in p53-deficient cells (Bischoff et al., 1996). 
A phase I study with E1B-55kDa gene deleted ONYX-015 was a 
proof of concept that oncolytic adenoviruses can be used for clinical 
oncolytic virotherapy. ONYX-015 was injected in head and neck and 
was well tolerated, nevertheless it was not efficient as a single agent 
and was combined with chemotherapy in phase II trials, and this 
strategy led to a better response and to a phase III study.  
However it should be remembered that when used as anticancer drugs, 
viruses must respect strict criteria for safety, efficacy and accessibility 
to pharmacological study in human subjects. Specificity for cancer 
tissues is the key to safety, and this goal can be achieved through 
strategies that take advantage by tumor-specific changes of cancer 
versus normal cells. In cancer treatments the response to oncolytic 
adenoviruses can be different from one individual to another one 
that’s why more specific and personalized approaches are required to 
optimize the oncolytic virus medicine. 
 
1.6 The metabolism of cancer cells 
 
In tumor cells is observed an increase in intensity of anaerobic 
glycolysis and occurs the phenomenon of aerobic glycolysis: the cells 
produce lactic acid even in the presence of oxygen. The appearance of 
an intense aerobic glycolysis in tumors was considered by Warburg as 
peculiar of neoplastic cells; however it is now known that the same 
phenomenon can be observed in normal tissues to rapid turnover, in 
embryonic tissue, in the retina and in the nervous tissue (Casson et al., 
2013). The main metabolic characteristic of cancer is the "Warburg 
effect" (Figure 6), which is to prefer, for the production of cellular 
energy even in aerobic conditions, the use of the glycolytic pathway 
rather than that of mitochondrial respiration. 
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Figure 6 The Warburg effect (Vander Heiden et al., 2009). Schematic 
representation of the differences between oxidative phosphorylation, anaerobic 
glycolysis and aerobic glycolysis. 
 
To survive and grow, normal cells metabolize glucose to pyruvate, 
which is completely oxidized to CO2 through the Krebs cycle and 
oxidative phosphorylation at the mitochondrial level, generating 36 
ATP for every molecule of glucose. The O2 is essential as a final 
electron acceptor, but when its concentration is limited, pyruvate is 
metabolized to lactate via anaerobic glycolysis. It is believed that the 
Warburg effect is dependent on the particular expression of some 
enzymes of the glycolytic pathway, such as hexokinase, 
phosphofructokinase and, above all, pyruvate dehydrogenase kinase. 
The most immediate consequence is that the neoplastic tissues are 
mainly glucose-dependent for their growth and for their energy 
balance, consequently the concentration of glucose that comes from 
outside is an index of ability for tumor cells. This explains why cancer 
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cells located away from the vessels undergo regressive processes and 
why tumors evade large amounts of glucose in the blood. 
 
1.7 The natural dipeptide L-carnosine and its functions 
 
L-carnosine (β-Ala-His) is a naturally occurring histidine 
dipeptide described as a component of the meat for the first time in 
1900 by Gulevitch. It is endogenously synthesized and normally found 
in the crystalline lens, kidney, stomach and, in particular, in the brain 
and in skeletal muscle in a range of concentrations of 0.3-5 mM and 2-
20 mM, respectively (Babizhayev et al., 1994). 
 
Figure 7 Structure of L-carnosine 
 
 
L-carnosine is synthesized in the liver, by carnosine synthase from its 
primary constituents, histidine and b-alanine. This dipeptide is then 
transported through the blood to peripheral tissues, where it is 
absorbed. It’s also introduced through the diet, in particular thanks to 
the meat; it is estimated that the average intake of L-carnosine roams 
on average between 50-250 mg / day. L-carnosine is absorbed in the 
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intestine unaltered, is distributed through the blood stream and used 
by peripheral tissues, metabolized into its constituent amino acids or 
filtered by the kidneys and excreted in the urine. Thanks to the 
presence of a β amino acid, L-carnosine is resistant to most of the 
known peptidases. The hydrolysis of L-carnosine is catalyzed by 
carnosinase. In human, two forms of carnosinase were discovered: 
serum carnosinase (CN1) and tissue carnosinase (CN2). CN1 was 
identified as a homodimeric dipeptidase with narrow substrate 
specificity whereas CN2 could exert dipeptidase activity on a wider 
range of substrates. Because of the existence of CN1 in human serum, 
the blood L-carnosine concentration is very low. Carnosinase present 
in the liver, kidney and serum is the enzyme that cleaves the L-
carnosine; therefore, the two isoforms, the serum and the tissue, have 
different molecular properties and substrate specificity: in the liver, L 
and D isomers of L-carnosine are hydrolyzed with the same speed, 
while in serum and kidney is cleaved only the isomer L. There are a 
number of compounds related to L-carnosine, with whom they share 
part of the structure and properties, and they are: anserine, 
homocarnosine, omoanserine, N Acetylcarnosine, N 
Acetylomocarnosine and N Acetylanserine (Boldyrev, 2012). 
 
L-carnosine performs multiple biological functions, including 
antioxidant activity, ability to chelate metal ions, as well as anti-
inflammatory and anti-senescence properties. L-carnosine can be 
defined as antioxidant due to its ability to act as protection against the 
harmful effects of highly reactive molecules known as free radicals. 
The gradual accumulation of damage caused by free radicals leads to a 
progressive weakening of the organism and an increased susceptibility 
to disease. The protective action exerted by the antioxidant molecules, 
including L-carnosine, may therefore be of particular utility in all 
physiological situations in which the organism is subjected to a high 
oxidative stress. Cell membranes, DNA, RNA and proteins are 
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particularly susceptible to oxidative damage. Moreover, being 
extremely soluble in water, it is able to inhibit the oxidation of cell 
membranes due to the action of the iron, zinc, copper, hydrogen 
peroxide, radical oxygen (Mzhel’skaia and Boldyrev, 1998). From the 
chemical point of view, L-carnosine has antioxidant activity due to the 
presence of the peptide bond which exerts a stabilizing action against 
the imidazole radical, in fact the antioxidant effect of the dipeptide has 
proved greater than the activity of single or combined amino acids 
which constitute L-carnosine (Babizhayev et al., 1994). 
 
Recently, L-carnosine has been defined as the mixture of nutrient 
longevity, as experimental studies indicate that it may delay the 
senescence and lead to cellular rejuvenation in cultured fibroblasts 
human. For this reason the dipeptide L-carnosine was defined as 
antiaging (Calabrese et al., 2010). L-carnosine inhibits the formation 
of the substances mentioned under the name of AGEs, advanced 
glycosylation end products, ultimate result of non-enzymatic 
glycosylation; also called the "Maillard reaction" in which the amino 
groups of the amino acids react with the carbonyl groups (aldehyde 
and ketone) of sugars, with the production of reactive chemical 
entities. All this leads to the formation of cross-links between different 
proteins with possible formation of advanced glycation end products, 
which exert a detrimental effect on cell function, in addition to 
increasing the formation of free radicals (Reddy et al., 2005). 
Regarding the role of L-carnosine in cellular aging, Holliday R and 
McFarland GA (2000) showed that in human fibroblasts in culture, 
physiological concentrations of L-carnosine (20 or 30 mM) prolonged 
the duration of their lives and reduced the characteristic signs of 
aging, allowing the maintenance of a juvenile phenotype. Instead, the 
removal of L-carnosine from the culture medium causes the 
immediate resumption of the aging process.  Indeed Shao et al. (2004) 
indicate that L-carnosine can reduce the shortening of telomeres. The 
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effect of the dipeptide on telomere shortening has been studied in 
human fetal fibroblasts (HPF). The experimental data show that cells 
grown in the presence of L-carnosine slow down telomere shortening 
compared to cells grown in the absence of L-carnosine. Aging is the 
accumulation of aberrant proteins, in particular those that have 
carbonyl groups. L-carnosine reacts with protein carbonyl groups in 
order to mask the deleterious effects of other molecules and facilitate 
their proteolytic destruction.  
 
The Antineoplastic effects of L-carnosine were first described by 
Nagai and Suda, (1986) in fact they subcutaneously implanted 
Sarcoma-180 tumour cells into ddY mice, the day after implantation 
L-carnosine (50 mg/kg/day) was injected subcutaneously and the 
treatment was continued every second day. Comparing the treatment 
with L-carnosine to the treatment with saline, the authors observed 
that the dipeptide inhibited tumour growth and also reduced mortality. 
Inspired by the work of (Holliday and McFarland, 1996) who found 
that L-carnosine selectively inhibited the growth of transformed and 
neoplastic cells, (Renner et al., 2010) showed that L-carnosine 
inhibited the growth of cultured tumour cells isolated from human 
glioblastoma. The L-carnosine effect was not accompanied by 
apoptosis or necrosis, but rather by a reduced proliferation, probably 
mediated by a block of ATP production, since this dipeptide prevents 
anaerobic glycolysis, that is the preferential route for energy 
production in tumor cells. Recently it was demonstrated that L-
carnosine inhibits proliferation in kidney mesangial cells and also 
DNA synthesis in a dose-dependent. In this cell cycle is arrested in the 
G1-S phase transition, this event is accompanied by a reduction of 
phosphorylation of ERK 1/2 and p38-MAPK, responsible of the 
survival and cell proliferation (Jia et al., 2009). L-carnosine has been 
shown to have an effect in vivo, in fact retards tumor growth in 
murine fibroblasts; although it is not able to completely prevent the 
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development of the tumor, considerably reduces the number of 
mitoses observed in tumor mass compared to a control sample treated 
only with NaCl. Tumor cells produce a greater quantity of 
deoxyribose, which gives them the ability to resist apoptosis, however 
this feature is lost after treatment with L-carnosine, for its ability to 
sequester deoxyribose (Hipkiss, 2011).A proteomic experiment 
evaluated the influence of L-carnosine on the activity of several 
proteins (Asperger et al., 2011). Cells isolated from patients with 
glioma and continuous cell lines of human glioblastoma (T98G), 
treated for 72h with 50mM of L-carnosine showed a significant 
reduction of protein in tumor progression. Among these are: the 
uroporphyrinogen decarboxylase (UROD), the enzyme in the 
biosynthetic pathway heme; the transaldolase (Taldo) involved in the 
oxidative pathway of the pentose phosphate, which is important in 
detoxification and in the production of D-Ribose. Transaldolase 
connects the pentose phosphate pathway intermediates to glycolysis 
and contribute to the survival of cancer cells. Another protein affected 
by treatment with L-carnosine is BAG2 (associated with Bcl-2) in turn 
regulated by p38 MAPK. Among the main functions of BAG2 is to 
inhibit the activity of the Hsp70-CHIP. The interaction of CHIP with 
the heat shock protein (HSP) is in the ubiquitination of the substrates 
and their degradation through the proteasome. 
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2 Aims of the study 
	  
Cancer is a major public health problem and new therapeutic 
approaches are needed. In fact, despite progress in reducing mortality 
due to improvements in cancer prevention, early detection and 
treatments, still 6.7 million deaths worldwide are caused by cancer 
each year (Parkin et al., 2002). In recent years considerable attention 
has been given to the use of natural substances as anticancer drugs. 
The natural antioxidant dipeptide L-carnosine belongs to this class of 
molecules because it has been proved to have a significant anticancer 
activity both in vitro and in vivo (Iovine et al., 2014). A number of 
biological functions have been recognized to this molecule, including 
antioxidant activity, ability to chelate metal ions, inhibition of protein 
glycosylation, anti-inﬂammatory and anti-senescence properties 
(Guiotto et al., 2005). Many authors have highlighted the anti-
proliferative activity of L-carnosine, showing that this dipeptide is 
able to inhibit the growth of cancer cells, affecting the HIF-1alpha 
signaling and anaerobic glycolysis (Renner et al. 2010; Iovine et al., 
2012; Iovine et al., 2014). In particular, in the laboratory were initially 
I have spent my doctoral fellowship, it has been demonstrated that L-
carnosine reduces the levels of ROS and ATP, which are two 
important molecules for tumor progression and that 50 mM of 
dipeptide is also able to reduce the number of colonies in colon cancer 
cells compared to control cells not treated (Iovine et al; 2014). A 
major characteristic of L-carnosine, which makes this dipeptide a 
good candidate for new therapeutic strategies, is its bioavailability. 
Indeed, the cellular uptake of drug-like molecules is the major 
obstacle in the development of a successful cancer therapy and the 
aim of new anti-cancer strategies is to facilitate the uptake and 
intracellular accumulation of drugs into cancer cells, reducing the non-
specific uptake into normal cells. From this point of view L-carnosine 
could represent a good adjuvant candidate for the treatment of cancer 
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due to its antiproliferative property and also because it is thought to be 
absorbed primarily via intestinal epithelium cells, for these reasons it 
can be used for the treatment of colon cancer (Iovine et al., 2014). 
However one of the limits of the use of L-carnosine is that high 
concentration of dipeptide is required to arrest tumor progression 
(Renner et al; 2010; Iovine et al; 2012) since the doses of L- carnosine 
used exceed those currently used in clinical settings. My first aim was 
to overcome this limitation studying the effect of L-carnosine at lower 
concentrations. To do this I joined the Immunovirotherapy lab in 
Helsinki where I took advantage of the new technology developed by 
the assistant Professor Vincenzo Cerullo. We have hypothesized that 
L-carnosine could be conjugated on the capsid of oncolytic viruses 
and this strategy would enhance the cell entry of the peptide. 
Oncolytic adenoviruses are a new class of anti-cancer agents with a 
great therapeutical potential since they can selectively kill cancer 
cells, in fact they can enter both normal and tumor cells but they are 
modified to be able to replicate only in cancerous cells leaving normal 
cells unharmed. Virus replication in tumor cells eventually leads to 
cell lyses, which allows the new virus progeny to spread to 
surrounding cells and even to distant metastases through circulation. 
Several clinical trials have revealed Ads as a safe and promising 
therapy for cancer (Harvey et al., 2002). 
Since the combination of Ads and chemotherapeutic drugs may 
improve the efficacy of oncolytic virotherapy, thanks to the 
synergistic action of virus and drug, in the present study we have 
optimized a model to use oncolytic adenovirus as a scaffold to deliver 
active drugs. Our working hypothesis was to use an oncolytic 
adenovirus as drug carrier, to achieve an increase of cellular death in 
cancer cells treated with the L-carnosine coated oncolytic adenovirus 
compared to cells treated with the drug or virus alone.  
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The purpose of my study was to: 
- Develop a new system to increase the amount of L-carnosine that is 
delivered to cancer cells by using viruses as carriers; 
- Generate an oncolytic adenovirus loaded with L-carnosine as a drug 
delivery system for cancer therapy;   
- Study the efficacy and the molecular mechanisms of the oncolytic 
virus loaded with L-carnosine compared to virus alone, in different 
cancer cell lines;  
- Analyze the efficacy of oncolytic adenovirus loaded with L-
carnosine in a lung and colon cancer xenograft model.  
The possible advantages of this approach are: the synergistic 
action of virus and drug and consequently an increased efficacy due to 
an increased drug-delivery to target cancer cells. The proposed model 
could be used as a novel drug delivery system for cancer therapy. 
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3 Materials and Methods 
 
3.1 Cell lines 
 
HCT-116 human colorectal carcinoma cell line was purchased 
from the American Type Culture Collection (ATCC) USA. The cell 
line was cultured at 37°C and 5% CO2 in DMEM (Dulbecco’s 
Modified Eagle Medium) purchased from Bio Whittaker Classic Cell 
Culture Media, Lonza - VWR International s.r.l. , supplemented with 
10% fetal bovine serum (FBS) (Gibco Laboratories, North Andover, 
Massachusetts) and 1% penicillin/streptomycin (Gibco Laboratories). 
SW-480, human colorectal carcinoma cell line was purchased from 
the American Type Culture Collection (ATCC) USA, were cultured in 
RPMI 1640 medium (BioWhittaker) supplemented with 10% fetal 
bovine serum (FBS) (Gibco Laboratories), 1% penicillin/streptomycin 
(GibcoLaboratories) and 1% L-glutamine (Gibco Laboratories). 
A2058 human melanoma cell line was purchased from the American 
Type Culture Collection (ATCC) USA. The cell line was cultured at 
37 °C and 5% CO2 in DMEM (Dulbecco’s Modified Eagle Medium) 
purchased from Bio Whittaker Classic Cell Culture Media, Lonza - 
VWR International s.r.l., supplemented with 10% fetal bovine serum 
(FBS) (Gibco Laboratories, North Andover, Massachusetts) and 1% 
penicillin/streptomycin (Gibco Laboratories). A549 lung cancer cell 
line was purchased from the American Type Culture Collection 
(ATCC) USA. The cell line was cultured at 37 °C and 5% CO2 in 
DMEM (Dulbecco’s Modified Eagle Medium) purchased from Bio 
Whittaker Classic Cell Culture Media, Lonza - VWR International 
s.r.l., supplemented with 10% fetal bovine serum (FBS) (Gibco 
Laboratories, North Andover, Massachusetts) and 1% 
penicillin/streptomycin (Gibco Laboratories). 
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3.2 Preparation of adenoviruses 
 
Ad5D24-CpG, a gift from Dr. Vincenzo Cerullo was generated 
(according to the protocol reported in Cerullo et al; 2012) recombining 
a CpG-rich shuttle plasmid (pTHSN-CpG1) with a plasmid containing 
the 24 adenovirus backbone. pTHSN-CpG1was constructed by 
inserting NdeI-digested CpG1 (derived by digestion from custom 
designed pU57-CpG1; GenScript, Piscataway, NJ) and SpeI-digested 
CpG2 sequences (derived by digestion from custom designed pU57-
CpG1; GenScript) respectively into NdeI- and Spe-I linearized 
plasmid pTHSN previously generated. Viral stocks were expanded in 
human lung cancer cell line A549 and purified on cesium chloride 
gradients. Stocks were stored at -80°C after the addition of glycerol to 
a concentration of 50% vol/vol. The viral particle concentration was 
determined by OD260-reading and standard TCID50 (tissue culture 
infectious dose 50) assay on 293 cells was performed to determine 
infectious particle (pfu) titer. Virus was characterized by PCR and 
restriction enzyme analysis. Protein concentration of viral prep was 
determined by Breadford Assay (Biorad). Ad5D24-Rfp, kindly 
provided by Dr. Masataka Suzuki from Baylor College of Medicine 
(USA). It was generated (according to the protocol reported in (Farzad 
et al., 2014) using standard adenovirus preparation techniques. In 
order to insert RFP gene into E3 region, the monomeric RFF 
complementary DNA was inserted into pTHSN. pAd5D24RFP was 
generated by homologous recombination in E.coli between linearized 
pTHSNRFP and linearized pAd5D24RFP. Ad5D24RFP virus genome 
was transfected in A549 cells for amplification and rescue. Viral 
particles (vp) were calculated according the following instructions: 
• Viral particle concentration (VP/ml) = A260 (blank corrected) 
x dilution factor x extinction coefficient. 
• Extinction coefficient = 1,10E+12 viral particles / ml / A260 
unit 
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• For VP calculations include only values which meet 
requirements: 1) A260 nm (raw data) should be between 0.1-
2.5 OD units (linear range of spectrophotometer), 2) 
A260/A280 ratio should be between 1.2-1.4 
 
 
3.3 Treatments 
 
L-carnosine was purchased from Sigma–Aldrich, and dissolved 
in PBS (Lonza-VWR International s.r.l.). A modified version of L-
carnosine (Carnosine6K), featuring six additional lysines at the C-
terminus, was purchased from GeneCust Europe Laboratoire de 
Biotechnologie du Luxembourg S.A, and dissolved in PBS (Lonza-
VWR International s.r.l). 
 
3.4 Complex formation 
 
In order to saturate the surface of the oncolytic adenovirus an 
excess of Carnosine6K has been used. Previous studies performed in 
the hosting laboratory, showed that a ratio of 1:500 virus-to-peptide 
protein amount is sufficient to efficiently coat the viral surface. To 
allow the formation of the complex between the oncolytic virus and 
Carnosine6K the two components need to be mixed and incubated at 
room temperature for 15 minutes using MilliQ H2O at pH 7.4 as 
buffer.  
 
3.5 Zeta Potential Analysis 
 
Zeta potential analysis has been performed using 1x 1010 viral 
particles (vp). According to the complex formation protocol, the viral 
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particles have been mixed with Carnosine6K. Naked oncolytic 
adenovirus Ad5D24CpG or Carnosine6Kalone have been used as 
controls. All the samples have been diluted in a volume of 800 ul of 
MilliQ H20 at pH 7.4 and injected with a 1 ml syringe in the capillary 
flow cell to measure the electric surface charge of the particles. An 
equilibration time of 120 seconds has been set on the software to 
allow the samples to stabilize at 25°C inside the measuration chamber. 
Three consecutive measurements have been performed on each 
sample using ZetaSizer Nano Malvern. 
 
 
3.6 Dynamic Light Scattering analysis 
 
As described in the previous section, complex and controls have 
been diluted in 800 ul of MilliQ H2O pH 7.4. The solution has been 
transferred to a transparent cuvette and analysed ZetaSizer Nano 
Malvern. After an equilibration period of 120 seconds, three 
consecutive measurements have been performed on each sample. 
 
3.7 Viability Assay 
 
Tumor cells were seeded at 1.0 × 104 cells per well on 96-well 
plates and maintained under appropriate condition (DMEM or RPMI 
1640, completed with 5% FBS, 1% L-glutammine and 1% of 
penicillin/streptomycin (all from Gibco Laboratories). On the next 
day, L-carnosine, Carnosine6K and Ad5D24-CpG virus were diluted 
separately in growth media with 2% FBS, cells were treated and then 
incubated in 5% FBS containing media at 37  °C for 3 to 5 days. Cell 
viability was determined by MTS according to the manufacturer's 
protocol (Cell Titer 96 AQueous One Solution Cell Proliferation 
Assay; Promega, Nacka, Sweden). The absorbance was measured with 
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a 96-wells plate spectrophotometer Varioskan Flash Multimode 
Reader at 490 nm. The experiments were independently performed 
three times and each experiment contained triple replicates. 
 
3.8 ATP determination Assay 
 
The ATP concentration was assessed quantitatively using the 
CellTiter-Glo Luminescent cell viability assay purchased from 
Promega Corp. (Madison, WI, USA, G7571) according to the 
manufacturer’s instructions.  Briefly, tumor cells were seeded at 1.0 × 
104 cells per well in white opaque 96-well plate (tissue culture treated, 
sterile-6005181, from Packard), in 100 ul of fresh culture medium 
containing DMEM without phenol red (Sigma–Aldrich). After 
incubation for 24 h at 37   °C in 5% CO2, L-carnosine, Carnosine6K 
and Ad5D24-CpG virus were diluted separately in culture medium 
with 2% FBS, cells were treated and then incubated in 5% FBS 
containing media at 37   °C for 3 to 5 days. Then, the ATP 
concentration was determined by CellTiter-Glo Reagent according to 
the manufacturer's protocol. The luminescence was measured with 
Varioskan Flash Multimode Reader. The experiments were 
independently performed three times and each treatment was 
performed in triplicate. 
 
3.9 Transduction Assay 
 
Cells were seeded at a density of 1x104cells/well in 96 well 
plates and maintained under appropriate condition (DMEM or RPMI 
1640, completed with 5% FBS, 1% L-glutammine and 1% of 
penicillin/streptomycin (all from Gibco Laboratories). On the 
following day cells have been infected using an oncolytic adenovirus 
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Ad5D24Rfp encoding for the red fluorescent protein (100vp, 10vp, 
1vp, 0.1vp) and complex (100vp, 10vp, 1vp, 0.1vp). Red fluorescence 
has been measured by Varioskan plate reader at 24h, 48h, and 72h 
after the treatment. The experiments were independently performed 
three times and each experiment contained triple replicates. 
 
3.10 Determination of infectious titer 
 
Cells were seeded at a density of 2x105 cells/well in 24 well 
plates, and maintained under appropriate condition (DMEM or RPMI 
1640, completed with 5% FBS, 1% L-glutammine and 1% of 
penicillin/streptomycin (all from Gibco Laboratories). On the 
following day cells were infected with Ad5D24CpG (100vp, 10vp, 
1vp, 0.1vp) and complex (protein plus Ad5D24CpG 100vp, 10vp, 
1vp, 0.1vp). Plates were centrifuged for 90 minutes with 1000 rcf in 
37   °C and incubated for 48h before staining at 37°C and 5% CO2.  48 
hours following the incubation cells were fixed by adding 250 ul of 
ice-cold methanol per well and incubated 15 minutes. Then cells were 
washed three times with PBS1%-BSA solution and incubated in the 
dark for one hour with 1st antibody, mouse monoclonal anti-hexon 
1:2000 (Novus Biological, NB600-413). After the incubation time, 
cells were washed three times with PBS1%-BSA and incubated in the 
dark for other 1 hour with 2nd antibody: Biotin-SP-conjugated goat 
anti-mouse 1:500 (Jackson Immuno Research, 115-065-062). After 
the incubation time, cells were washed three times with PBS1%-BSA 
and incubated in the dark for 30 minutes with extravidin-peroxidase 
(Sigma Aldrich, E2886). Finally cells were washed three times like as 
indicated earlier and treated with Dab solution (Sigma Aldrich, 
A7284-50ML). To quench the reaction, cells were treated with PBS 
1x. The detection of infectious titer was made using microscope 
EVOS, each well was photographed (5pcs) at five non-overlapping 
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sites. Infected cells were counted using ImageJ and the infectious titer 
was calculated according to the following equation: 
Infectious titer: x !(!"##)!(!"#$%) !! !"#!  
Where x= number of infected (stainend cells) 
A(24 well)= 190 mm2 
A (field) = surface area of the field 
L= dilution 
V= volume of virus dilution applied per well 
 
3.11 Analysis of apoptotic and necrotic cells 
 
Tumor cells were plated into 6 well plates, 2x105 cells/well. 
Cells were treated with L-carnosine (100mM), Carnosine6K, 
Ad5d24CpG (100vp) or PBS for mock. The amount of apoptotic and 
necrotic cells were measured after 24 and 48 hours p.i. with a TACS 
Annexin V-FITC kit (Trevigen Inc., Gaitherburg, MD, US) and BD 
LSR II flow cytometer according to manufacture´s instructions. The 
analysis of apoptotic cells was performed by annexin V (annexin V-
FITC) assay with fluorescein isothiocyanate (FITC)-labels. This 
method allows the analysis of the percentage of apoptotic cells. In 
early stages of apoptosis, phosphatidyl-serine is expressed in the 
membrane, and in the late phase of apoptosis, it binds annexin as 
propidium iodide enters into the cells. Experiments were performed 
three times in triplicate. 
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3.12 Western blot Analysis 
 
Total extracts of HCT116 and A549 cell lines were prepared 24 
and 48 h after treatment with L-carnosine 100mM, Carnosine6K and 
Ad5D24CpG 100 MOI. Briefly, harvested cells were washed twice 
with ice-cold PBS and centrifuged at 700 rpm for 5 min at 4  °C. The 
cell pellet was resuspended with cold lysis buffer containing: Cell 
Lysis Buffer (NP40, Invitrogen FNN0021), Protease inhibitor cocktail 
(Sigma Aldrich P2714-1BTL) and PMSF (Phenylmethylsulfonyl 
fluoride Sigma Aldrich, P 7626), for 30 min on ice. The cell lysates 
were cleared by centrifugation at 13000 rpm for 10 min at 4  °C. 
Protein concentration was determined by a Bio-Rad protein assay kit 
(Bio-Rad Laboratories). For the western blot analysis, proteins were 
challenged with antibodies against p62 (mouse antibody from 
Abnova), LC3 (rabbit antibody from Cell Signalling) and b-actin 
(mouse monoclonal from Santa Cruz Biotechnology). The signals 
were detected by using ECL kit (GE Healthcare). 
 
3.13 Animal experiments 
 
All animal experiments were reviewed and approved by the 
Experimental Animal Committee of the University of Helsinki and the 
Provincial Government of Southern Finland. Mice were obtained from 
Scanbur (Karlslunde, DK) at 5-7 weeks of age and quarantined at least 
for 2 weeks before the study. Health status of the mice was frequently 
monitored and as soon as signs of pain or distress were evident they 
were euthanized. For the efficacy experiment human xenografts were 
established by injecting 1 × 106 A549 and HCT-116 cells s.c. into the 
flanks of 5-7 week-old female BALB/c nude mice (N = 5 per group). 
Tumors (two tumors per mouse, ~5x5 mm in diameter) were injected 
i.t. with a volume of 50  µl for three times on days 0,2,5with 108 
VP/tumor of Ad5D24CpG and control tumors were injected with PBS 
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only. The formula (length × (width)2 × 0.5) was used to calculate the 
tumor volumes. Mice were euthanized when a tumor reached an 
average diameter of 15  mm. 
 
 
3.14 Statistical Analysis 
 
Statistical significance was determined by unpaired, two-tailed 
Student's t-test using GraphPad Prism 6 (GraphPad Software, Inc., La 
Jolla, CA, US).  Differences in tumor growth were analyzed with the 
nonparametric Mann–Whitney test (immundeficent mouse 
experiments). Results are presented as mean ±SEM for tumor growth 
and in vitro studies. All p values were two-sided and considered 
statistically significant when ≤ 0.05. * p <0.05, ** p <0.01, *** p 
<0.001, **** p <0.0001.  
Therapeutic synergy was assessed using the fractional tumor volume 
(FTV) method (Xu et al., 2011) (Yokoyama et al., 2000) which is 
derived from a method originally developed by Webb (Webb 1963). 
Here, the expected FTV (i.e., the product of FTV values for 
monotherapies) of the combination therapy is divided by the observed 
FTV of the combination, yielding a ratio that indicates the nature of 
the interaction >1 indicates synergy and <1 indicates a less than 
additive effect). FTV for each experimental group is obtained by 
dividing the mean tumor volume of the experimental group by the 
mean tumor volume of the control group. 
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4 Results 
 
4.1 Modified L-carnosine (Carnosine6K) can be attached into the 
capsid of an oncolytic adenovirus through electrostatic 
interaction 
 
Since the main purpose of this study was to develop a new 
system to increase the amount of L-carnosine that is delivered to cells 
by using virus as carrier, we have developed a strategy to combine 
virus and L-carnosine, based on electrostatic interaction. The first step 
for the characterization of the novel system was to study how the 
peptide can be conjugated to the surface of an oncolytic adenovirus. It 
is known that the surface of an oncolytic adenovirus is negatively 
charged, hence we have hypothesized that L-carnosine positively 
charged consisting of a tail of six lysines (Carnosine6K) can be mixed 
with the oncolytic adenovirus to allow the formation of the complex 
formed by the virus and Carnosine6K (Figure 8). The carrier used for 
our experiments is a serotype 5 conditionally-replicating adenovirus 
that features a 24 base pair deletion in E1A gene. This deletion makes 
this virus able to replicate only in cells that show a disrupted 
retinoblastoma pathway, i.e many cancer cells. Ad5D24CpG virus is 
also enriched with CpG islands to stimulate the innate immune system 
through toll-like receptor 9 (TLR9) (Cerullo V et al; 2012). Since the 
Zeta Potential is the electrical potential that exists at the shear plane of 
a particle and is a function of the surface charge of a particle, we have 
analyzed the electric surface charge (Z-Potential) of the complex to 
see if the addition of the Carnosine6K was able to change the negative 
charge of the adenovirus into positive. We observed that mixing 
Carnosine6K with oncolytic adenovirus (1:500) the electric surface 
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charge became very positive compared to the virus alone and 
Carnosine6K alone (Figure 9a). We have also analyzed the Dynamic 
light scattering (DSL) of the singles particles and we reported the 
results in function of the peptide concentration (Figure 9b). 
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Figure 8. Oncolytic adenovirus as a carrier for active drugs. Our working 
hypothesis is to use an oncolytic adenovirus, which expressing immunomodulatory 
molecules, together with active peptides as a carrier for active drugs. 
 
 
 
Figure 9 a,b.  Complex formation between oncolytic adenovirus and modified 
L-carnosine. 1x1010viral particles were conjugated with positively charged L-
carnosine (1:500). After the reaction the surface charge of the single particles was 
measured. Complex shows an increase in the Zeta Potential (9a). We also tested the 
size of the single particles and the diameter of the Carnosine6k slightly increases, 
however no significant aggregation is observed (9b). 
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4.2 Effect of Carnosine6K coated viruses on cell viability and ATP 
levels 
 
In order to characterize the infectivity and the cell killing 
activity of the complex we have performed MTS cell viability assays 
on four different human cancer cell lines (human lung cancer cell line 
A549, HCT116 human colon cancer cell line with a mutation in codon 
13 of the Ras proto-oncogene, SW-480 human colon cancer cell line 
with a mutation in codon 12 of the Ras proto-oncogene, A2058 human 
melanoma cell line with a mutation in BRAF), comparing the efficacy 
of cell killing of the complex with an uncoated oncolytic virus, 
Carnosine6K alone and L-carnosine 100mM (Figure 10a, b, c, d). 
The MTS cell viability assays shows that 100vp of the complex is able 
to reduce cell viability even more than the virus alone in all tested cell 
lines (p <0.001). It is known that high concentration of L-carnosine 
(100mM) reduce ATP levels in HCT116 cell line (Iovine et al; 2012), 
so we have checked the levels of ATP by ATP assays in all four 
cancer cell lines (Figure 11a, 11b, 11c, 11d). The ATP production 
was found significantly reduced especially in the complex 100vp 
compared to the virus alone and L-carnosine alone with or without six 
lysines. 
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Figure 10 a, b, c, d. In vitro killing of human cancer cell lines. Cell viability was 
performed by MTS Assay on four cancer cell lines, in order to evaluate if the 
coating of the viral capsid with Carnosine6K could affect the biological properties of 
oncolytic viruses. 
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Figure 11 a, b, c, d. Carnosine6K coated virus reduced ATP levels in human 
cancer cell lines.  In order to evaluate if the Carnosine6K coated virus is able to 
influence ATP production in human cancer cell lines the ATP levels were measured 
quantitatively using the CellTiter-Glo Luminescent cell viability assay.  
 
4.3 Carnosine6K coated viruses display increased transduction and 
enhanced infectious titer 
 
To examine whether the presence of Carnosine6K affects the 
transduction efficacy of the adenoviral vector, we have performed a 
transduction assay using on a panel of different human tumor cell 
lines, using an oncolytic adenovirus expressing red-fluorescent protein 
(RFP) to assess the transduction efficacy of the coated complex in 
comparison to the naked oncolytic adenovirus. We compared the 
transduction efficacy of Ad5D24Rfp uncoated virus and Ad5D24Rfp-
Carnosine6K complex. Reading of the fluorescent signal checked by 
Varioskan has been performed 24, 48 and 72 hours post-infection 
(p.i.) as showed in figure 12. Interestingly at 72 h p.i. the amount of 
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fluorescent cells is significantly higher when cells have been treated 
with complex in comparison to cells treated with naked oncolytic 
adenovirus. In fact the transduction assay shows that cells were more 
transduced in the complex 100 vp than in the virus alone in all four 
tested cell lines after 72h post-infection (Figure 12 a, b, c, d).   
 
In order to determine the infectious titer based on visual quantification 
of cells infected with an uncoated oncolytic virus Ad5D24CpG, 
Ad5D24CpG-Carnosine6K complex added as a single entity and 
Ad5D24CpG and Carnosine6K added separately as a mix, we 
performed an Immunocytochemistry assay (ICC). The levels of 
infectious titer was higher in the complex than in the virus alone at a 
condition of 10vp in all four cell lines tested (Figure 13 a, b, c, d), 
especially in A549 cell line where we found that the titer is one log 
higher in the complex. 
 
Figure 12 a, b, c, d. In vitro transduction efficacy. Transduction efficacy was 
evaluated in A549, HCT-116, SW480 and A2058 cell lines by infection with an 
oncolytic adenovirus encoding for the red fluorescent protein with or without 
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Carnosine6K. Red fluorescence was measured using Varioskan plate reader 24, 48 
and 72h post infection. 
 
 
Figure 13 a, b, c, d. Carnosine6K coated virus shows high infectious titer in 
different human cancer cell lines. The infectious titer of Ad5D24CpG, 
Ad5D24CpG-Carnosine6K, Complex, and Ad5D24CpG-Carnosine6K mixed we 
performed an ICC assay. The target molecule in the assay is the virus hexon protein, 
an antigen associated with the viral capsule. Upon the infection, cells synthesize 
excessive amount of hexon proteins, which are targeted by first antibody. This 
mouse-origin antibody, in turn, is targeted by the second biotin-sp-conjugated 
antibody, which functions as a platform for extravidine peroxidase. After the 
addition of the stain, dab is oxidized by peroxidase, forming an insoluble brown 
precipitate which gives the infected cells an intense dark color. 
 
 
 
 
 
 
 
 
Results 
 
52 
 
 
4.4 Complex can induce apoptotic and necrotic cell death 
 
Apoptosis is a physiological response to exogenous and 
endogenous death signals. In particular a prerequisite for tumor 
growth is the inactivation of apoptotic pathways which is also 
responsible for therapy resistance (Sjöström and Bergh, 2001). It has 
been demonstrated that L-carnosine treatment at concentration 100 
mM is able to induce late apoptosis only in a small number of cells 
(Iovine et al; 2012), thus we studied the ability of the complex to 
induce apoptotic and necrotic cell death. We measured the amount of 
Annexin-V positive, i.e. early apoptotic cells, and propidium iodide 
(PI), i.e. late apoptotic/necrotic cells 24 and 48 hours after the 
treatment in all four cell lines (Figure 14 a, b, c, d). The levels of fold 
change at 48/24 hours of both the early and the late apoptotic/necrotic 
cells were elevated in the complex in all tested cell lines, especially in 
A549 and HCT-116 cell lines, compared to the virus alone and L-
carnosine alone with or without six lysines. 
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Figure 14 a, b, c, d. Induction of apoptotic and necrotic cell death. Early 
apoptotic and late apoptotic or necrotic cells are presented as fold change at 48/24 
hours after infection.  The amount of early apoptotic and late apoptotic or necrotic 
cells 24 and 48 hours after virus infection were analyzed by flow cytometry from 
A549, HCT-116, SW480, A2058 cell lines. FITC-labeled Annexin-V was used to 
indicate the early apoptotic cells and PI (propidium iodide) the necrotic or late 
apoptotic cells. 
 
4.5 Complex induces autophagy activation 
 
We have investigated whether oncolytic adenovirus loaded with 
Carnosine6K can induce autophagy in HCT116 and A549 cell lines. 
One hallmark of autophagy activation is the formation of cellular 
autophagosome containing LC3-II. In the mammalian the precursor 
form of LC3 is post-modified into two forms, LC3-I and LC3-II. LC3-
I is localized in the cytosol, then, it is cleaved by cysteine protease 
Atg4 to generate lapidated form LC3-II that specifically localizes in 
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autophagosomal membranes. The amount of LC3-II or the LC3-
II/LC3-I ratio can be used to estimate the abundance of 
autophagosomes before they are destroyed through fusion with 
lysosomes (Mizushima and Yoshimori). In fact, the LC3-II conversion 
and integration into autophagosomal membrane, is one of the major 
sign of the activation of the autophagic process. We have analyzed the 
activation of autophagy in HCT116 and A549 cell lines. Cells were 
infected with an oncolytic adenovirus loaded with Carnosine6K 
respect to adenovirus alone or mix. Proteins were collected at 0, 24, 
48 hours post treatment. An immunoblotting assay was used to reveal 
the two active species of LC3, the upper band corresponding to LC3-I 
(19Kd) and lower band corresponding to LC3-II (17Kd)(Kabeya, 
2000). As shown in Figure 15 (a, b) in HCT116, complex promotes 
autophagy by increasing the conversion LC3-I to LC3-II, 24 and 48h 
post-infection. However, the best results were obtained 48h post-
infection where the complex respect to adenovirus alone induces a 
complete conversion of LC3-I in LC3-II. In addition, in A549 
complex promotes the conversion of LC3-I to LC3-II, 24h post-
infection, respect to adenovirus alone or mix, while we could not find 
a different ratio LC3-II/LC3-I after 48h. Meanwhile we have 
evaluated by western blotting analysis the intracellular levels of p62 
(Figure 16), a protein that is degraded through autophagy, and we 
have found that protein levels were decreased in both cancer cells.  
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Figure 15 a, b Induction of autophagy. LC3 II/LC3 I ratio in HCT-116 and A549 
cell lines. Cells were infected with an oncolytic adenovirus loaded with 
Carnosine6K respect to adenovirus alone or mix.  Proteins were collected t 24 and 
48 hours post treatment. An immunoblotting assay was used to reveal LC3. 
 
 
a b 
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Figure 16 a, b, c, d. Analysis of the intracellular levels of p62. p62/actin ratio was 
in A549 and HCT-116 cell lines. Cells were infected with an oncolytic adenovirus 
loaded with Carnosine6K respect to adenovirus alone or mix.  Proteins were 
collected at 24 and 48 hours post treatment. An immunoblotting assay was used to 
reveal p62. 
 
4.6 Complex displays increased efficacy in vivo in a xenograft 
model of lung and colon cancer 
 
The oncolytic activity of the complex was tested in a lung and 
colon cancer xenograft model. Nude mice bearing A549 and HCT-116 
cell tumors in the flanks were treated intratumorally with 1x108 
VP/tumor of viruses (or PBS) on days 0, 2, 5 and the tumor growth 
was followed over time. We observed that the tumor growth was 
a b 
c d 
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significantly (p <0.001 at day 18) reduced in both complex treated 
mice compared to the control virus and carnosine6k alone (Fig. 17a, 
b). The intratumoral administration of the complex resulted in a clear 
tumor reduction and most of the tumors were fully cured within 18 
days after the first virus injection. In tumor growth follow-up studies 
we observed that tumor growth of mice treated with complex was 
significantly suppressed compared to the mice treated with virus alone 
or mix. 
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Fig 17 a, b. In vivo efficacy of the complex. Nude mice bearing A549 and HCT-
116 tumors were treated intratumorally with PBS (mock) or with 1x108vp/ tumor of  
Ad5D24CpG or Ad5D24CpG-Carnosine6K virus on days 0, 2 and 5. Tumor growth 
was measured over time. 
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Figure 18a Xenograft HCT-116 cancer mouse model, Figure 18b Xenograft 
A549 cancer mouse model. Nude BALB/c mice bearing A549 and HCT-116 
tumors were treated intratumorally with PBS (mock) or with 1x108vp/ tumor of  
Mock Carnosine
6K 
Complex 
Mix Virus 
Mock 
Carnosine
6K 
Complex 
Virus Mix 
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Ad5D24CpG or Ad5D24CpG-Carnosine6K virus on days 0, 2 and 5. Tumor growth 
was measured over time. 
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5 Discussion 
 
The ability of virus to kill cancer cells has been known for more 
than a century (Kelly and Russell, 2007). Their antitumor potency is 
due to several mechanisms, including direct lysis, apoptosis, 
expression of toxic proteins, autophagy, arrest of protein synthesis and 
induction of antitumoral immunity. Oncolytic adenoviruses are 
modified in order to be able to selectively kill cancer cells. Normal 
tissue is kept safe since viruses are targeted in different ways towards 
tumor cells leaving normal cells unharmed (Khuri FR et al; 2000). 
Although much is known about oncolytic adenoviruses, improvements 
to enhance their efficacy are still needed. Since every tumor and 
patient is unique, different researches have thought to arm oncolytic 
adenovirus coupled with chemotherapy (Siurala et al., 2014). One way 
to enhance gene delivery to tumor tissue is to create modified 
adenoviruses capsid for targeted cancer delivery. An example is 
Ad5/3-D24-GMCSF which is a chimeric oncolytic adenovirus, coding 
for granulocyte-macrophage colony-stimulating factor (GM-CSF), 
where fiber 5 knob was replaced by serotype knob 3 domain. This 
virus was modified to selectively replicate in p16/Rb defective cells, 
including human cancer cells. Ad5/3-D24-GMCSF, also called 
ONCOS-102, showed safety and efficacy in cancer patients both as a 
single agent and in combination with cyclophosphamide or low-dose 
pulse temozolomide (Koski et al., 2010). Another strategy to enhance 
transduction efficacy and prolongate the circulation time of the viruses 
is to attach the adenoviral surface by adding Polyethylene glycol 
(PEG). The covalent attachment of PEG to the viral capsid reduces 
hepatotoxicity and cytotoxicity in mice (Wonganan and Croyle, 2010). 
Furthermore, the major obstacle in the development of an effective 
cancer therapy is the cellular uptake of drug-like molecule. For this 
reason, the new anti-cancer strategies aim to deliver and facilitate the 
uptake and intracellular accumulation of drugs into cancer cells, while 
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reducing the non-specific uptake into normal cells. From this point the 
natural dipeptide L-carnosine could represent a good adjuvant 
candidate for the treatment of colon cancer for its bioavailability and 
because it is absorbed primarily via intestinal epithelium cells (Son et 
al 2004). In addition, recently the antioxidant dipeptide L-carnosine it 
has been the subject of study by our and others research group, for its 
significant anticancer activity both in vitro and in vivo. In fact, it has 
been reported that L-carnosine could inhibit mesangial cell 
proliferation by modulating cell cycle progression and affecting the 
proliferation of tumor cells in mouse (Jia et al., 2009). Furthermore, it 
has been demonstrated that the effect of the dipeptide on proliferation 
of tumor cells is related to an inhibition of ATP production and 
consequently to an anaerobic glycolysis (Renner et al; 2010). In 
addition, we have recently observed that treatment with 50-100mM of 
L-carnosine inhibits the proliferation of human colorectal carcinoma 
cells by affecting the ATP and Reactive Oxygen Species (ROS) 
production (Iovine B. et al., 2012). We have also found that L-
carnosine reduces the HIF-1α protein level affecting its stability and 
decreases the HIF-1 transcriptional activity (Iovine B. et al., 2014). In 
order to enhance the antineoplastic properties of L-carnosine, reducing 
the high concentration of peptide required to arrest tumor progression, 
and to improve the viral transduction and replication, we have 
developed a new treatment strategy against cancer.  
The present study is focused on the development of a model to use an 
oncolytic adenovirus as a scaffold to deliver active drugs.  
First, we have developed a strategy to conjugate peptides on 
viral capsid, based on electrostatic interactions. L-carnosine can be 
modified by adding a tail of six lysines, named as Carnosine6K, and 
finally attached to the negatively charged viral capsid. To proof the 
concept of our novel strategy, we carried out in vitro studies to 
analyze the electric surface charge. We have found that Carnosine6K 
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positively charged, can be combined with the surface of oncolytic 
adenovirus that is negatively charged, allowing the formation of a 
complex (Ad5D24CpG-Carnosine6K). The result was a change of 
charge from negative in the virus condition into positive in the 
complex condition.  
Then, we have evaluated the biological function of the complex to 
better characterize the infectivity and the cancer cell killing activity. 
We have found, by performing a viability assay, that modified 
Carnosine6K (8mM) can reduce cancer cell viability as well as L-
carnosine (100mM) in all tested cancer cell lines (A549, HCT-116, 
SW480, A2058). In addition, we have demonstrated that 100vp of the 
complex (Ad5D24CpG-Carnosine6K) is able to reduce cell viability 
even more than the uncoated oncolytic virus. Previously, Iovine et al. 
have observed that treatment with 50-100mM of L-carnosine 
decreased the levels of ATP in all four cancer cell lines analyzed. 
Therefore, we have evaluated ATP levels, by comparing each other 
Carnosine6K, the virus alone or the complex. The complex reduced 
ATP production, especially 100vp (80-90%), more significantly than 
uncoated oncolytic virus (12%) or Carnosine6K.  
Next we have also investigated whether the presence of Carnosine6K 
affects the transduction efficacy of the oncolytic adenovirus by 
performing a transduction assay. We compared the transduction 
efficacy of Ad5D24Rfp uncoated virus with Ad5D24Rfp-
Carnosine6K complex. We have found that the amount of fluorescent 
cells is significantly higher in cells that have been treated with 
Ad5D24Rfp-Carnosine6K complex, especially using 100vp of 
complex at 72 h post-infection, compared to cells treated with naked 
oncolytic adenovirus. In addition, we have showed, by an 
immunocytochemistry assay, that also the infectious titer of the 
complex was higher at a condition of 10vp, compared to naked 
oncolytic adenovirus or a mix with virus and Carnosine6k added 
separately. These results demonstrated that virus alone or with 
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Carnosine6k added separately in a mixture have the same infectious 
titer, suggesting stronger infectivity properties of the complex. 
Interestingly we found that in A549 cell line the titer is one log higher 
in the complex compared to the other conditions. However further 
investigation on this mechanism are needed. The inactivation of 
apoptotic pathways is mainly responsible for tumor growth. Therefore 
from the therapeutic point of view, it is necessary to induce apoptosis 
in cancer cells in order to improve the efficacy of cancer therapy. It 
has been shown that L-carnosine treatment at a concentration of 100 
mM induced late apoptosis only in a small number of cells (Iovine et 
al., 2012). According to these observations, we have evaluated the 
ability of the complex to induce apoptotic and necrotic cell death. 
We have found that Carnosine6K is able to induce apoptosis and 
necrosis, as well as L-carnosine 100mM, in all four cell lines that we 
have analyzed. However, we found that the complex is able to induce 
apoptosis and necrosis, especially in A549 and HCT116 cell lines.  
Finally, we have investigated the possible molecular mechanisms 
underlying the synergistic effect between Carnosine6K and the 
oncolytic adenovirus. For this purpose we have investigated whether 
oncolytic adenovirus loaded with Carnosine6K can induce autophagy 
in HCT116 and A549 cell lines. One hallmark of autophagy activation 
is the formation of cellular autophagosome containing LC3-II. In the 
mammalian the precursor form of LC3 is post-modified into two 
forms, LC3-I and LC3-II. LC3-I is localized in the cytosol and it is 
then cleaved by cysteine protease Atg4 to generate lapidated form 
LC3-II that specifically localizes in the autophagosomal membranes. 
The amount of LC3-II or the LC3-II/LC3-I ratio can be use to estimate 
the abundance of autophagosomes before they are destroyed through 
fusion with lysosomes (Mizushima et al., 2001). In fact, the LC3-II 
conversion and integration into autophagosomal membrane, is one of 
the major sign of activation of the autophagic process. We have found 
that an oncolytic adenovirus coated with Carnosine6K increases the 
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autophagy by promoting the conversion of LC3-I to LC3-II and 
decreasing levels of p62 protein. The p62 protein is degraded during 
autophagy and may serve to link ubiquitinated proteins to the 
autophagic machinery, to enable their degradation in lysosome. Since 
p62 accumulates when autophagy is inhibited and decreases when 
autophagy is induced, the analysis of its levels may be used as marker 
to study the autophagic flux, in response to pro-autophagic stimuli 
(Puissant et al., 2012). Our results support the idea that Carnosine6K 
and an oncolytic adenovirus, delivered as a single entity have a 
synergistic effect. These results suggest that the enhanced oncolytic 
potency of complex is, at least in part, due to the fact that the L-
carnosine modified, as Carnosine6K, increases cancer autophagy by 
improving the efficacy of Ad-mediated oncolysis. Some authors have 
reported that some oncolytic viruses can reverse the autophagic 
pathway, by promoting their replication (Jackson et al. 2005). 
However, as a single therapeutic agent an oncolytic adenovirus could 
not efficiently destroy the large tumor mass in patients (Kirn, 2001; 
McCormick, 2003; Zhao et al., 2003). In fact adenoviruses alone 
induce autophagy activation, even if there are many evidences that 
chemotherapeutic agents can increase cancer cell autophagy, by 
improving the efficacy of oncolytic virotherapy (Koski et al., 2010).  
In the end we have investigated the efficacy in vivo of the complex 
in human colon cancer and lung cancer xenograft model. Horii Y et 
al. demonstrated that the intraduodenal administration of L-carnosine 
decreases splenic sympathetic nerve activity (splenic-SNA) and 
inhibits the proliferation of a human colon cancer cell line HCT116 
implanted into athymic BALB/c nude mice. In vivo data revealed that 
1mg/ml of L-carnosine solution given in the drinking water from 6 to 
22 days inhibited tumor proliferation. Starting from these results we 
have evaluated that the intratumoral administration of the complex 
resulted in a clear tumor reduction and most of the tumors were fully 
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eradicated within 18 days after the virus injection. In tumor growth 
follow-up studies we observed that tumor growth of mice treated with 
complex was significantly suppressed compared to the mice treated 
with virus alone. These results are in agreement with the synergistic 
effect between Carnosine6K and oncolytic adenovirus that we have 
found in vitro. 
5.1 Conclusions 
 
Cancer is still a leading cause of death worldwide. Although 
many kinds of treatment have been developed during the past decades, 
there is still a lack of effective therapy for advanced cancer. Many 
studies have shown that oncolytic adenoviruses have been used in 
clinical trials and in cancer treatments (Koski et al., 2010; 
McCormick, 2003; Crompton and Kirn, 2007). Oncolytic virotherapy 
is emerging as a potential approach to treat cancer, using viruses 
which are specifically engineered to selectively infect, replicate in and 
kill cancer cells without causing damage to normal cells. In this study 
we are proposing a novel strategy using oncolytic adenovirus as a 
scaffold to deliver active drugs. We have demonstrated that the 
dipeptide L-carnosine can be modified by adding a tail of polylisines 
on the viral capsid through an electrostatic interaction between 
positively charged Carnosine6K and the viral capsid which is 
negatively charged. Furthermore, we have shown in vitro and in vivo 
that the complex Carnosine6K with oncolytic adenoviruses 
(Ad5D24CpG-Carnosine6K) has a synergistic effect. In addition, the 
complex decreases cell viability of human cancer cells enhances the 
transduction efficacy and the infectious titer. We have also 
investigated the possible molecular mechanisms underlying the 
synergistic effect between Carnosine6K and the oncolytic adenovirus, 
and we have observing that an oncolytic adenovirus loaded with L-
Carnosine6K can induce autophagy in both HCT116 and A549 cancer 
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cell lines. The in vivo efficacy of the complex was performed in 
human colon cancer and lung cancer xenograft model. The 
intratumoral injection of the complex has efficiently reduced tumor 
growth and most of the tumors were fully eradicated within 18 days 
after the treatment. In conclusion, the results described in this study 
encourage the use of Ad5D24CpG-Carnosine6K for new therapeutic 
protocols for the treatment of cancer and in particular human colon 
cancer and lung cancer. Moreover the use of oncolytic adenoviruses 
loaded with active drugs could be used as a novel drug delivery 
system for cancer therapy. 
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